Product Code: 4968
The antiviral drugs market is slated to witness notable expansion through 2028 driven by surging incidences of antiviral infections across the globe.
The onset of COVID-19 prompted massive R&D activities worldwide to find effective therapeutic remedies for the novel coronavirus infection. As a result, increased focus on the development of novel drugs for viral infections like COVID-19 has been favorable for the product landscape during the pandemic.
The antiviral drugs market has been categorized on the basis of drug class, indication, type, age group, and region. Based on drug class, the market has been further segregated into reverse transcriptase inhibitors, neuraminidase inhibitors, protease inhibitors, DNA polymerase inhibitors, and others.
The others sub-segment was valued at nearly USD 18 billion in 2021 and is anticipated to register solid revenue growth over 2022-2028 primarily driven by continuous developments and advancements in drug therapies. Combination therapy offers several advantages, such as high bioavailability, shelf life, and efficacy. Prevalent usage of combination therapy for enhanced patient outcomes is set to accelerate segmental growth through the assessment timeframe.
In terms of indication, the industry has been classified into HIV AIDS, influenza, herpes simplex virus (HSV), hepatitis, coronavirus infection, and others. The antiviral drugs market size from the influenza sub-segment is slated to witness robust expansion at about 2.8% CAGR between 2022 and 2028 on account of prominent R&D activities. High recurrence of seasonal flu as well as continuous changes in strain would create need for drug development, which is likely to stimulate segmental progress.
By type, the market has been bifurcated into generic and branded. In 2021, the branded sub-segment held more than 71% share in the market and is projected to observe strong growth over the review timeline. Greater effectiveness of branded drugs and extensive product pipelines are foreseen to boost product adoption. Moreover, strong presence of key market players is expected to positively influence segmental revenue in the coming years.
With respect to age group, the antiviral drugs market has been segmented into pediatric, adult, and geriatric. The geriatric sub-segment garnered over USD 20 billion in revenue in 2021 and is speculated to grow at a considerable rate through 2028. High prevalence of sexually transmitted diseases among the geriatric population, along with high healthcare spendings and presence of large patient pool, is primed to propel segmental expansion.
In the regional landscape, the Latin America antiviral drugs market accounted for around 3.7% of the overall industry revenue in 2021 and is estimated to reach a sizable revenue by the end of 2028 owing to increasing occurrences of COVID-19 and HIV, coupled with growing awareness regarding available treatments across the region. Furthermore, market participants are implementing several growth strategies to broaden their market footprints, which is forecast to promote market growth in LATAM in the future.
Table of Contents
Chapter 1 Methodology
- 1.1 Market definitions
- 1.2 Base estimates and working
- 1.2.1 North America
- 1.2.2 Europe
- 1.2.3 Asia Pacific
- 1.2.4 Latin America
- 1.2.5 MEA
- 1.3 Forecast calculations
- 1.4 Data validation
- 1.5 Data sources
- 1.5.1 Secondary
- 1.5.1.1 Paid sources
- 1.5.1.2 Unpaid sources
- 1.5.2 Primary
Chapter 2 Executive Summary
- 2.1 Antiviral drugs market industry 360 degree synopsis
- 2.1.1 Business trends
- 2.1.2 Drug class trends
- 2.1.3 Indication trends
- 2.1.4 Type trends
- 2.1.5 Age group trends
- 2.1.6 Regional trends
Chapter 3 Antiviral Drugs Market Industry Insights
- 3.1 Industry segmentation
- 3.2 Industry landscape, 2017 - 2028 (USD Million)
- 3.3 Industry impact forces
- 3.3.1 Growth drivers
- 3.3.1.1 Rising prevalence of viral infections including COVID-19
- 3.3.1.2 Increasing number of product launches for HIV treatment
- 3.3.1.3 High investment in R&D activities and presence of pipeline products
- 3.3.1.4 Increasing geriatric population
- 3.3.2 Industry pitfalls & challenges
- 3.3.2.1 Presence of generics
- 3.3.2.2 Rising awareness about preventive drugs treatment
- 3.3.2.3 Drug resistance
- 3.4 Growth potential analysis
- 3.4.1 By drug class
- 3.4.2 By indication
- 3.4.3 By type
- 3.4.4 By age group
- 3.5 COVID-19 impact analysis
- 3.6 Regulatory landscape
- 3.7 Porter's analysis
- 3.8 Competitive landscape, 2021
- 3.9 PESTEL analysis
Chapter 4 Antiviral Drugs Market, By Drug Class
- 4.1 Key segment trends
- 4.2 DNA polymerase inhibitors
- 4.2.1 Market size, by region, 2017 - 2028 (USD Million)
- 4.3 Reverse transcript inhibitors
- 4.3.1 Market size, by region, 2017 - 2028 (USD Million)
- 4.4 Protease inhibitors
- 4.4.1 Market size, by region, 2017 - 2028 (USD Million)
- 4.5 Neuraminidase inhibitors
- 4.5.1 Market size, by region, 2017 - 2028 (USD Million)
- 4.6 Others
- 4.6.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 5 Antiviral Drugs Market, By Indication
- 5.1 Key segment trends
- 5.2 Influenza
- 5.2.1 Market size, by region, 2017 - 2028 (USD Million)
- 5.3 HIV AIDS
- 5.3.1 Market size, by region, 2017 - 2028 (USD Million)
- 5.4 Hepatitis
- 5.4.1 Market size, by region, 2017 - 2028 (USD Million)
- 5.5 Herpes simplex virus (HSV)
- 5.5.1 Market size, by region, 2017 - 2028 (USD Million)
- 5.6 Coronavirus infection
- 5.6.1 Market size, by region, 2017 - 2028 (USD Million)
- 5.7 Others
- 5.7.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 6 Antiviral Drugs Market, By Type
- 6.1 Key segment trends
- 6.2 Branded
- 6.2.1 Market size, by region, 2017 - 2028 (USD Million)
- 6.3 Generic
- 6.3.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 7 Antiviral Drugs Market, By Age Group
- 7.1 Key segment trends
- 7.2 Adult
- 7.2.1 Market size, by region, 2017 - 2028 (USD Million)
- 7.3 Pediatric
- 7.3.1 Market size, by region, 2017 - 2028 (USD Million)
- 7.4 Geriatric
- 7.4.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 8 Antiviral Drugs Market, By Region
- 8.1 Key regional trends
- 8.2 North America
- 8.2.1 Market size, by country, 2017 - 2028 (USD Million)
- 8.2.2 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.2.3 Market size, by indication, 2017 - 2028 (USD Million)
- 8.2.4 Market size, by type, 2017 - 2028 (USD Million)
- 8.2.5 Market size, by age group, 2017 - 2028 (USD Million)
- 8.2.6 U.S.
- 8.2.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.2.6.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.2.6.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.2.6.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.2.7 Canada
- 8.2.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.2.7.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.2.7.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.2.7.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.3 Europe
- 8.3.1 Market size, by country, 2017 - 2028 (USD Million)
- 8.3.2 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.3.3 Market size, by indication, 2017 - 2028 (USD Million)
- 8.3.4 Market size, by type, 2017 - 2028 (USD Million)
- 8.3.5 Market size, by age group, 2017 - 2028 (USD Million)
- 8.3.6 Germany
- 8.3.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.3.6.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.3.6.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.3.6.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.3.7 UK
- 8.3.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.3.7.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.3.7.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.3.7.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.3.8 France
- 8.3.8.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.3.8.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.3.8.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.3.8.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.3.9 Spain
- 8.3.9.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.3.9.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.3.9.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.3.9.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.3.10 Italy
- 8.3.10.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.3.10.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.3.10.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.3.10.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.3.11 Russia
- 8.3.11.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.3.11.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.3.11.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.3.11.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.3.12 Poland
- 8.3.12.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.3.12.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.3.12.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.3.12.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.3.13 Switzerland
- 8.3.13.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.3.13.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.3.13.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.3.13.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.3.14 The Netherlands
- 8.3.14.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.3.14.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.3.14.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.3.14.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.3.15 Sweden
- 8.3.15.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.3.15.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.3.15.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.3.15.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.4 Asia Pacific
- 8.4.1 Market size, by country, 2017 - 2028 (USD Million)
- 8.4.2 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.4.3 Market size, by indication, 2017 - 2028 (USD Million)
- 8.4.4 Market size, by type, 2017 - 2028 (USD Million)
- 8.4.5 Market size, by age group, 2017 - 2028 (USD Million)
- 8.4.6 Japan
- 8.4.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.4.6.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.4.6.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.4.6.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.4.7 China
- 8.4.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.4.7.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.4.7.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.4.7.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.4.8 India
- 8.4.8.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.4.8.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.4.8.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.4.8.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.4.9 Australia
- 8.4.9.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.4.9.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.4.9.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.4.9.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.4.10 South Korea
- 8.4.10.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.4.10.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.4.10.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.4.10.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.4.11 Singapore
- 8.4.11.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.4.11.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.4.11.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.4.11.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.4.12 Indonesia
- 8.4.12.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.4.12.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.4.12.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.4.12.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.4.13 Thailand
- 8.4.13.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.4.13.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.4.13.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.4.13.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.4.14 Malaysia
- 8.4.14.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.4.14.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.4.14.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.4.14.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.4.15 Philippines
- 8.4.15.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.4.15.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.4.15.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.4.15.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.5 Latin America
- 8.5.1 Market size, by country, 2017 - 2028 (USD Million)
- 8.5.2 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.5.3 Market size, by indication, 2017 - 2028 (USD Million)
- 8.5.4 Market size, by type, 2017 - 2028 (USD Million)
- 8.5.5 Market size, by age group, 2017 - 2028 (USD Million)
- 8.5.6 Brazil
- 8.5.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.5.6.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.5.6.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.5.6.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.5.7 Mexico
- 8.5.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.5.7.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.5.7.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.5.7.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.5.8 Argentina
- 8.5.8.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.5.8.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.5.8.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.5.8.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.6 Middle East & Africa
- 8.6.1 Market size, by country, 2017 - 2028 (USD Million)
- 8.6.2 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.6.3 Market size, by indication, 2017 - 2028 (USD Million)
- 8.6.4 Market size, by type, 2017 - 2028 (USD Million)
- 8.6.5 Market size, by age group, 2017 - 2028 (USD Million)
- 8.6.6 Saudi Arabia
- 8.6.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.6.6.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.6.6.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.6.6.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.6.7 South Africa
- 8.6.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.6.7.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.6.7.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.6.7.4 Market size, by age group, 2017 - 2028 (USD Million)
- 8.6.8 UAE
- 8.6.8.1 Market size, by drug class, 2017 - 2028 (USD Million)
- 8.6.8.2 Market size, by indication, 2017 - 2028 (USD Million)
- 8.6.8.3 Market size, by type, 2017 - 2028 (USD Million)
- 8.6.8.4 Market size, by age group, 2017 - 2028 (USD Million)
Chapter 9 Company Profiles
- 9.1 Competitive dashboard, 2021
- 9.2 Gilead Sciences, Inc
- 9.2.1 Business overview
- 9.2.2 Financial data
- 9.2.3 Product landscape
- 9.2.4 Strategic outlook
- 9.2.5 SWOT analysis
- 9.3 Johnson & Johnson
- 9.3.1 Business overview
- 9.3.2 Financial data
- 9.3.3 Product landscape
- 9.3.4 Strategic outlook
- 9.3.5 SWOT analysis
- 9.4 GlaxoSmithKline
- 9.4.1 Business overview
- 9.4.2 Financial data
- 9.4.3 Product landscape
- 9.4.4 Strategic outlook
- 9.4.5 SWOT analysis
- 9.5 AbbVie, Inc
- 9.5.1 Business overview
- 9.5.2 Financial data
- 9.5.3 Product landscape
- 9.5.4 Strategic outlook
- 9.5.5 SWOT analysis
- 9.6 Merck & Co.,
- 9.6.1 Business overview
- 9.6.2 Financial data
- 9.6.3 Product landscape
- 9.6.4 Strategic outlook
- 9.6.5 SWOT analysis
- 9.7 Bristol Myers Squibb
- 9.7.1 Business overview
- 9.7.2 Financial data
- 9.7.3 Product landscape
- 9.7.4 Strategic outlook
- 9.7.5 SWOT analysis
- 9.8 Aurobindo Pharma Limited
- 9.8.1 Business overview
- 9.8.2 Financial data
- 9.8.3 Product landscape
- 9.8.4 Strategic outlook
- 9.8.5 SWOT analysis
- 9.9 Sun Pharmaceutical Industries Ltd
- 9.9.1 Business overview
- 9.9.2 Financial data
- 9.9.3 Product landscape
- 9.9.4 Strategic outlook
- 9.9.5 SWOT analysis
- 9.10 Cipla, Inc.
- 9.10.1 Business overview
- 9.10.2 Financial data
- 9.10.3 Product landscape
- 9.10.4 Strategic outlook
- 9.10.5 SWOT analysis
- 9.11 Mylan N.V.
- 9.11.1 Business overview
- 9.11.2 Financial data
- 9.11.3 Product landscape
- 9.11.4 Strategic outlook
- 9.11.5 SWOT analysis